News from the European Society of Cardiology Congress — Physician’s First Watch
News from the European Society of Cardiology Congress
By the NEJM Journal Watch Editors
This week, NEJM Journal Watch and CardioExchange have been bringing you news and analyses from the European Society of Cardiology Congress in Amsterdam, the Netherlands. Here are some highlights:
SAVOR-TIMI 53 and EXAMINE: In two placebo-controlled trials, the diabetes drugs saxagliptin and alogliptin neither decreased nor increased the incidence of major adverse CV events over roughly 2 years.
Hokusai-VTE: In a noninferiority trial among patients with symptomatic venous thromboembolism, the investigational drug edoxaban had similar efficacy to warfarin, with lower rates of bleeding.
RE-ALIGN: In patients with mechanical heart valves, dabigatran was associated with higher rates of both thrombotic and bleeding events, compared with warfarin.
TASTE: Thrombus aspiration before percutaneous coronary intervention showed no mortality advantage over PCI alone at 30 days in patients with ST-segment-elevation MI.
PRAMI: Restricting revascularization to culprit lesions during primary PCI led to a significantly higher rate of cardiac death, nonfatal MI, or refractory angina.
ACCOAST: Giving prasugrel before coronary angiography was not more efficacious than just-in-time administration and significantly increased bleeding.
For even more conference coverage, visit CardioExchange's ESC.13 Headquarters at the link below.